by Paul | 11th June 2025 | News
London and New York, NY, June 11, 2025. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for...
by Paul | 19th May 2025 | News
London and New York, NY, May 19, 2025. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for...
by Paul | 1st May 2025 | News
London and New York, NY, May 1, 2025. OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular condition associated with chronic and often severe pain but...
by Paul | 30th April 2025 | News
Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo‑controlled trial. OKYO Pharma plans to analyze the efficacy data from the 17 patients who have now...
by Paul | 31st March 2025 | News
Urcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term Stability Urcosimod stable in single-use ampoules for more than 2½ years FDA requires drug to show long-term shelf stability for approval Daily administration to patients via...
by Paul | 10th March 2025 | News
London and New York, NY, March 10, 2025. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for...
